186 related articles for article (PubMed ID: 28292762)
1. GPR40 reduces food intake and body weight through GLP-1.
Gorski JN; Pachanski MJ; Mane J; Plummer CW; Souza S; Thomas-Fowlkes BS; Ogawa AM; Weinglass AB; Di Salvo J; Cheewatrakoolpong B; Howard AD; Colletti SL; Trujillo ME
Am J Physiol Endocrinol Metab; 2017 Jul; 313(1):E37-E47. PubMed ID: 28292762
[TBL] [Abstract][Full Text] [Related]
2. SCO-267, a GPR40 Full Agonist, Improves Glycemic and Body Weight Control in Rat Models of Diabetes and Obesity.
Ueno H; Ito R; Abe SI; Ookawara M; Miyashita H; Ogino H; Miyamoto Y; Yoshihara T; Kobayashi A; Tsujihata Y; Takeuchi K; Watanabe M; Yamada Y; Maekawa T; Nishigaki N; Moritoh Y
J Pharmacol Exp Ther; 2019 Aug; 370(2):172-181. PubMed ID: 31182471
[TBL] [Abstract][Full Text] [Related]
3. GPR40 full agonism exerts feeding suppression and weight loss through afferent vagal nerve.
Ueno H; Ito R; Abe SI; Ogino H; Maruyama M; Miyashita H; Miyamoto Y; Moritoh Y; Tsujihata Y; Takeuchi K; Nishigaki N
PLoS One; 2019; 14(9):e0222653. PubMed ID: 31525244
[TBL] [Abstract][Full Text] [Related]
4. GPR40 partial agonists and AgoPAMs: Differentiating effects on glucose and hormonal secretions in the rodent.
Pachanski MJ; Kirkland ME; Kosinski DT; Mane J; Cheewatrakoolpong B; Xue J; Szeto D; Forrest G; Miller C; Bunzel M; Plummer CW; Chobanian HR; Miller MW; Souza S; Thomas-Fowlkes BS; Ogawa AM; Weinglass AB; Di Salvo J; Li X; Feng Y; Tatosian DA; Howard AD; Colletti SL; Trujillo ME
PLoS One; 2017; 12(10):e0186033. PubMed ID: 29053717
[TBL] [Abstract][Full Text] [Related]
5. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K
Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371
[TBL] [Abstract][Full Text] [Related]
6. Mercaptoacetate blocks fatty acid-induced GLP-1 secretion in male rats by directly antagonizing GPR40 fatty acid receptors.
Li AJ; Wang Q; Dinh TT; Simasko SM; Ritter S
Am J Physiol Regul Integr Comp Physiol; 2016 Apr; 310(8):R724-32. PubMed ID: 26791830
[TBL] [Abstract][Full Text] [Related]
7. Selective release of gastrointestinal hormones induced by an orally active GPR39 agonist.
Grunddal KV; Diep TA; Petersen N; Tough IR; Skov LJ; Liu L; Buijink JA; Mende F; Jin C; Jepsen SL; Sørensen LME; Achiam MP; Strandby RB; Bach A; Hartmann B; Frimurer TM; Hjorth SA; Bouvier M; Cox H; Holst B
Mol Metab; 2021 Jul; 49():101207. PubMed ID: 33711555
[TBL] [Abstract][Full Text] [Related]
8. Yhhu4488, a novel GPR40 agonist, promotes GLP-1 secretion and exerts anti-diabetic effect in rodent models.
Guo DY; Li DW; Ning MM; Dang XY; Zhang LN; Zeng LM; Hu YH; Leng Y
Biochem Biophys Res Commun; 2015 Oct; 466(4):740-7. PubMed ID: 26417688
[TBL] [Abstract][Full Text] [Related]
9. GPR40 is partially required for insulin secretion following activation of beta3-adrenergic receptors.
Pang Z; Wu N; Zhang X; Avallone R; Croci T; Dressler H; Palejwala V; Ferrara P; Tocci MJ; Polites HG
Mol Cell Endocrinol; 2010 Aug; 325(1-2):18-25. PubMed ID: 20416356
[TBL] [Abstract][Full Text] [Related]
10. Effects of long-term dipeptidyl peptidase-IV inhibition on body composition and glucose tolerance in high fat diet-fed mice.
Liu X; Harada N; Yamane S; Kitajima L; Uchida S; Hamasaki A; Mukai E; Toyoda K; Yamada C; Yamada Y; Seino Y; Inagaki N
Life Sci; 2009 Jun; 84(25-26):876-81. PubMed ID: 19358859
[TBL] [Abstract][Full Text] [Related]
11. GLP-2 receptor signaling controls circulating bile acid levels but not glucose homeostasis in Gcgr
Patel A; Yusta B; Matthews D; Charron MJ; Seeley RJ; Drucker DJ
Mol Metab; 2018 Oct; 16():45-54. PubMed ID: 29937214
[TBL] [Abstract][Full Text] [Related]
12. A new synthetic dual agonist of GPR120/GPR40 induces GLP-1 secretion and improves glucose homeostasis in mice.
Bianchini G; Nigro C; Sirico A; Novelli R; Prevenzano I; Miele C; Beguinot F; Aramini A
Biomed Pharmacother; 2021 Jul; 139():111613. PubMed ID: 33895521
[TBL] [Abstract][Full Text] [Related]
13. Optimization of physicochemical properties of pyrrolidine GPR40 AgoPAMs results in a differentiated profile with improved pharmacokinetics and reduced off-target activities.
Jurica EA; Wu X; Williams KN; Haque LE; Rampulla RA; Mathur A; Zhou M; Cao G; Cai H; Wang T; Liu H; Xu C; Kunselman LK; Antrilli TM; Hicks MB; Sun Q; Dierks EA; Apedo A; Moore DB; Foster KA; Cvijic ME; Panemangalore R; Khandelwal P; Wilkes JJ; Zinker BA; Robertson DG; Janovitz EB; Galella M; Li YX; Li J; Ramar T; Jalagam PR; Jayaram R; Whaley JM; Barrish JC; Robl JA; Ewing WR; Ellsworth BA
Bioorg Med Chem; 2023 May; 85():117273. PubMed ID: 37030194
[TBL] [Abstract][Full Text] [Related]
14. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
Vergès B; Bonnard C; Renard E
Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
[TBL] [Abstract][Full Text] [Related]
15. Incretin hormones: Their role in health and disease.
Nauck MA; Meier JJ
Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():5-21. PubMed ID: 29364588
[TBL] [Abstract][Full Text] [Related]
16. The GPR40 Full Agonist SCO-267 Improves Liver Parameters in a Mouse Model of Nonalcoholic Fatty Liver Disease without Affecting Glucose or Body Weight.
Ookawara M; Matsuda K; Watanabe M; Moritoh Y
J Pharmacol Exp Ther; 2020 Oct; 375(1):21-27. PubMed ID: 32719069
[TBL] [Abstract][Full Text] [Related]
17. GPR119 is required for physiological regulation of glucagon-like peptide-1 secretion but not for metabolic homeostasis.
Lan H; Vassileva G; Corona A; Liu L; Baker H; Golovko A; Abbondanzo SJ; Hu W; Yang S; Ning Y; Del Vecchio RA; Poulet F; Laverty M; Gustafson EL; Hedrick JA; Kowalski TJ
J Endocrinol; 2009 May; 201(2):219-30. PubMed ID: 19282326
[TBL] [Abstract][Full Text] [Related]
18. Co-agonist of glucagon and GLP-1 reduces cholesterol and improves insulin sensitivity independent of its effect on appetite and body weight in diet-induced obese C57 mice.
Patel V; Joharapurkar A; Dhanesha N; Kshirsagar S; Patel K; Bahekar R; Shah G; Jain M
Can J Physiol Pharmacol; 2013 Dec; 91(12):1009-15. PubMed ID: 24289070
[TBL] [Abstract][Full Text] [Related]
19. Novel GLP-1/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice.
Wismann P; Pedersen SL; Hansen G; Mannerstedt K; Pedersen PJ; Jeppesen PB; Vrang N; Fosgerau K; Jelsing J
Physiol Behav; 2018 Aug; 192():72-81. PubMed ID: 29540315
[TBL] [Abstract][Full Text] [Related]
20. Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery.
Svane MS; Jørgensen NB; Bojsen-Møller KN; Dirksen C; Nielsen S; Kristiansen VB; Toräng S; Wewer Albrechtsen NJ; Rehfeld JF; Hartmann B; Madsbad S; Holst JJ
Int J Obes (Lond); 2016 Nov; 40(11):1699-1706. PubMed ID: 27434221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
